Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Macquarie Group Ltd.

Macquarie Group Ltd. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 84.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,580 shares of the medical research company’s stock after purchasing an additional 4,853 shares during the quarter. Macquarie Group Ltd.’s holdings in Charles River Laboratories International were worth $2,082,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund raised its stake in Charles River Laboratories International by 417.3% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,288 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,039 shares during the last quarter. Mawer Investment Management Ltd. grew its holdings in Charles River Laboratories International by 49.4% in the 2nd quarter. Mawer Investment Management Ltd. now owns 8,923 shares of the medical research company’s stock valued at $1,909,000 after buying an additional 2,951 shares in the last quarter. Federated Hermes Inc. grew its holdings in Charles River Laboratories International by 9.3% in the 2nd quarter. Federated Hermes Inc. now owns 212,868 shares of the medical research company’s stock valued at $45,547,000 after buying an additional 18,196 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in Charles River Laboratories International by 7.2% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 9,148 shares of the medical research company’s stock valued at $1,801,000 after buying an additional 613 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Charles River Laboratories International by 6.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,059 shares of the medical research company’s stock valued at $2,767,000 after buying an additional 804 shares in the last quarter. 97.80% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

CRL opened at $202.54 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.08 and a debt-to-equity ratio of 0.91. The firm has a market cap of $10.33 billion, a price-to-earnings ratio of 21.39, a PEG ratio of 1.52 and a beta of 1.36. The stock’s 50-day moving average price is $236.02 and its 200 day moving average price is $221.23. Charles River Laboratories International, Inc. has a 12-month low of $181.36 and a 12-month high of $308.15.

Charles River Laboratories International (NYSE:CRL – Get Rating) last posted its quarterly earnings results on Wednesday, February 22nd. The medical research company reported $2.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.75 by $0.23. The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.04 billion. Charles River Laboratories International had a return on equity of 20.98% and a net margin of 12.23%. Charles River Laboratories International’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same quarter last year, the company earned $2.49 EPS. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.26 earnings per share for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 4,558 shares of the stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $254.41, for a total value of $1,159,600.78. Following the sale, the executive vice president now owns 6,010 shares of the company’s stock, valued at approximately $1,529,004.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Birgit Girshick sold 3,205 shares of the firm’s stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $254.39, for a total transaction of $815,319.95. Following the sale, the chief operating officer now owns 41,038 shares of the company’s stock, valued at approximately $10,439,656.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Shannon M. Parisotto sold 4,558 shares of the firm’s stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $254.41, for a total value of $1,159,600.78. Following the sale, the executive vice president now directly owns 6,010 shares in the company, valued at approximately $1,529,004.10. The disclosure for this sale can be found here. Insiders have sold 27,763 shares of company stock valued at $6,974,921 in the last quarter. Corporate insiders own 1.10% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on CRL shares. Robert W. Baird upped their target price on Charles River Laboratories International from $275.00 to $285.00 and gave the company an “outperform” rating in a report on Wednesday, January 11th. Credit Suisse Group lowered their price target on Charles River Laboratories International from $280.00 to $260.00 and set an “outperform” rating for the company in a report on Thursday, February 23rd. Citigroup lowered their price target on Charles River Laboratories International from $280.00 to $260.00 and set a “buy” rating for the company in a report on Thursday, February 23rd. Morgan Stanley lowered their price target on Charles River Laboratories International from $241.00 to $230.00 and set an “equal weight” rating for the company in a report on Thursday, February 23rd. Finally, Jefferies Financial Group cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, January 12th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and an average target price of $270.83.

Charles River Laboratories International Profile

(Get Rating)

Charles River Laboratories International, Inc is an early-stage contract research company, which provides research models required in the research and development of new drugs, devices, and therapies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.